RJA
GSK icon

Raymond James & Associates’s GSK GSK Stock Holding History

Raymond James & Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$800K Buy
+20,000
New +$818K ﹤0.01% 2827
2023
Q1 		– Sell
-79,100
Closed -$15.8K – 3947
2022
Q4 		$15.8K Sell
79,100
-400
-0.5% -$13.3K ﹤0.01% 3818
2022
Q3 		$12K Sell
79,500
-740
-0.9% -$28K ﹤0.01% 3845
2022
Q2 		$71K Buy
80,240
+17,040
+27% +$941K ﹤0.01% 3744
2022
Q1 		$16K Buy
63,200
+800
+1% +$43.5K ﹤0.01% 4029
2021
Q4 		$43K Sell
62,400
-14,640
-19% -$762K ﹤0.01% 3966
2021
Q3 		$19K Buy
77,040
+1,040
+1% +$52.2K ﹤0.01% 4008
2021
Q2 		$38K Buy
76,000
+62,800
+476% +$3.02M ﹤0.01% 3939
2021
Q1 		$9K Hold
13,200
– – ﹤0.01% 3958
2020
Q4 		$20K Sell
13,200
-51,840
-80% -$2.38M ﹤0.01% 3685
2020
Q3 		$12K Buy
65,040
+880
+1% +$44.1K ﹤0.01% 3536
2020
Q2 		$20K Buy
64,160
+2,400
+4% +$123K ﹤0.01% 3439
2020
Q1 		$39K Sell
61,760
-480
-0.8% -$25.6K ﹤0.01% 3344
2019
Q4 		$195K Sell
62,240
-1,920
-3% -$107K ﹤0.01% 3355
2019
Q3 		$44K Buy
+64,160
New +$3.3M ﹤0.01% 3483
2019
Q2 		– Sell
-62,080
Closed -$12K – 3688
2019
Q1 		$12K Sell
62,080
-800
-1% -$40K ﹤0.01% 3561
2018
Q4 		$4K Sell
62,880
-960
-2% -$47.3K ﹤0.01% 3496
2018
Q3 		$4K Sell
63,840
-320
-0.5% -$16.3K ﹤0.01% 3606
2018
Q2 		$4K Buy
+64,160
New +$3.23M ﹤0.01% 3555
2017
Q3 		– Sell
-52,720
Closed -$27K – 3433
2017
Q2 		$27K Buy
52,720
+2,800
+6% +$149K ﹤0.01% 3233
2017
Q1 		$28K Buy
+49,920
New +$2.53M ﹤0.01% 3189
2016
Q4 		– Sell
-51,280
Closed -$6K – 3298
2016
Q3 		$6K Buy
51,280
+7,200
+16% +$395K ﹤0.01% 3184
2016
Q2 		$17K Buy
44,080
+31,040
+238% +$1.64M ﹤0.01% 2945
2016
Q1 		$3K Buy
+13,040
New +$649K ﹤0.01% 2914

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's GSK Position: Q3 2024 in Review

Raymond James & Associates reduced its GSK (GSK) stake by 2.1% in Q3 2024, selling an estimated $981K and leaving 1,141,789 shares worth $46.7M. The position accounts for 0.03% of the portfolio, ranked #463.

Raymond James & Associates first reported a position in GSK in Q2 2013 and has held it in 46 quarters since. The position peaked at $174M in Q3 2017. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

  • Raymond James & Associates held 1,141,789 shares of GSK worth $46.7M as of Q3 2024.
  • Raymond James & Associates sold 23,983 GSK shares in Q3 2024, an estimated $981K.
  • GSK made up 0.03% of Raymond James & Associates's portfolio in Q3 2024, its #463 holding.
  • Raymond James & Associates first reported a position in GSK in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's GSK position peaked at $174M in Q3 2017.
  • 899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.